Novo Nordisk A/S

🇩🇰Denmark

Country: 🇩🇰Denmark

Ownership: Public

Established: 1923-01-01

Employees: 63.3K

Market Cap: $602.2B

Website: http://www.novonordisk.com

Clinical Trials

The Effect of Liraglutide Versus Placebo When Added to Basal Insulin Analogues With or Without Metformin in Subjects With Type 2 Diabetes

Phase 3

Completed

Conditions: Diabetes Mellitus, Type 2
Diabetes

Interventions: Drug: placebo
Drug: liraglutide

First Posted Date: 2012-06-12

Last Posted Date: 2017-03-08

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 451

Registration Number: NCT01617434

Locations: 🇷🇸
Novo Nordisk Investigational Site, Nis, Serbia

Safety and Tolerability of Liraglutide in Japanese Subjects With Type 2 Diabetes

Phase 1

Completed

Conditions: Diabetes
Diabetes Mellitus, Type 2

Interventions: Drug: liraglutide
Drug: placebo

First Posted Date: 2012-06-11

Last Posted Date: 2017-01-25

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 15

Registration Number: NCT01615978

Locations: 🇯🇵
Novo Nordisk Investigational Site, Tokyo, Japan

First Human Dose Trial of NNC0215-0384 in Subjects With Rheumatoid Arthritis

Phase 1

Completed

Conditions: Inflammation
Rheumatoid Arthritis

Interventions: Drug: NNC0215-0384
Drug: placebo

First Posted Date: 2012-06-05

Last Posted Date: 2017-02-27

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 36

Registration Number: NCT01611688

Locations: 🇩🇪
Novo Nordisk Investigational Site, Berlin, Germany

Effect of Repaglinide on Postprandial Lipemia in Type 2 Diabetes

Phase 4

Completed

Conditions: Diabetes
Diabetes Mellitus, Type 2

Interventions: Drug: repaglinide
Drug: glyburide

First Posted Date: 2012-05-25

Last Posted Date: 2017-02-20

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 51

Registration Number: NCT01605773

Locations: 🇺🇸
Novo Nordisk Investigational Site, Houston, Texas, United States

Non-interventional Study of Patients Using Norditropin® for Growth Hormone Deficiency or Turner Syndrome

Completed

Conditions: Growth Hormone Disorder
Growth Hormone Deficiency in Children
Genetic Disorder
Turner Syndrome

Interventions: Drug: somatropin

First Posted Date: 2012-05-23

Last Posted Date: 2015-07-03

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 2016

Registration Number: NCT01604161

A Pilot Study to Determine the Impact of Clopidogrel (Plavix®) on Bleeding Associated With Punch Biopsies in Healthy Volunteers

Phase 1

Completed

Conditions: Haemostasis
Healthy

Interventions: Drug: clopidogrel
Drug: placebo

First Posted Date: 2012-05-22

Last Posted Date: 2016-11-25

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 18

Registration Number: NCT01603342

Locations: 🇺🇸
Novo Nordisk Investigational Site, Neptune, New Jersey, United States

Activated Recombinant Human Factor VII in Pelvic-acetabular Fracture Reconstruction

Phase 2

Completed

Conditions: Acquired Bleeding Disorder
Trauma

Interventions: Drug: placebo
Drug: activated recombinant human factor VII

First Posted Date: 2012-05-18

Last Posted Date: 2017-01-13

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 48

Registration Number: NCT01601457

Locations: 🇬🇧
Novo Nordisk Investigational Site, London, United Kingdom

Activated Recombinant Human Factor VII in Patients With Dengue Haemorrhagic Fever

Phase 2

Completed

Conditions: Dengue Haemorrhagic Fever
Acquired Bleeding Disorder

Interventions: Drug: activated recombinant human factor VII
Drug: placebo

First Posted Date: 2012-05-18

Last Posted Date: 2017-01-11

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 28

Registration Number: NCT01601613

Locations: 🇹🇭
Novo Nordisk Investigational Site, Ubonratchathani, Thailand

A Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of NNC0148-0000-0362 in Healthy Subjects

Phase 1

Completed

Conditions: Healthy
Diabetes
Diabetes Mellitus, Type 2

Interventions: Drug: NNC 0148-0000-0362
Drug: insulin glargine
Drug: placebo

First Posted Date: 2012-05-14

Last Posted Date: 2015-05-29

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 83

Registration Number: NCT01597713

Investigation of 2 Different Oral Formulations of Estradiol and Norethisterone in Healthy Women

Phase 1

Completed

Conditions: Menopause
Healthy

Interventions: Drug: 2 mg estradiol / 1 mg norethisterone acetate (NETA)

First Posted Date: 2012-05-10

Last Posted Date: 2015-03-18

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 44

Registration Number: NCT01596010

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy